¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Celsite Venous Drug System Misc"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • social security system
    »çȸº¸ÀåÁ¦µµ
  • urinary system
    ºñ´¢°èÅë, ºñ´¢°è
  • urogenital system
    ºñ´¢»ý½Ä±â°èÅë, ºñ´¢»ý½Ä±â°è
  • vascular system
    Ç÷°ü°èÅë, Ç÷°ü°è
  • vegetative nervous system
    ½Ä¹°½Å°æ°èÅë, ½Ä¹°½Å°æ°è
  • value system
    °¡Ä¡Ã¼°è
  • antiallergic drug
    ¾Ë·¹¸£±â¾à, Ç׾˷¹¸£±âÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antianxiety drug
    Ç׺ҾÈÁ¦, ºÒ¾ÈÄ¡·áÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticancer drug
    Ç×¾ÏÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
  • antidiabetic drug
    ´ç´¢º´¾à
  • antiemetic drug
    ±¸Åä¾à, Ç×±¸ÅäÁ¦
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹ÎÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • parasympathetic drug
    ºÎ±³°¨½Å°æ¾à
  • parasympathomimetic drug
    ºÎ±³°¨ÈïºÐÁ¦
  • prokinetic drug
    À§Àå¿îµ¿ÃËÁøÁ¦
  • psychedelic drug
    ȯ°¢Á¦
  • psychoactive drug
    Á¤½ÅÀÛ¿ë¾à
  • sulfa drug
    ¼úÆÄÁ¦
  • sympathomimetic drug
    ±³°¨½Å°æÈïºÐÁ¦
  • synthetic drug
    ÇÕ¼º¾à
  • topical drug
    ±¹¼Ò¾à
  • tranquilizing drug
    Á¤½Å¾ÈÁ¤Á¦, Á¤¿ÂÁ¦
  • tuberculostatic drug
    Ç×°áÇÙÁ¦
  • vasoactive drug
    Ç÷°üÀÛ¿ë¾à
  • fixed drug eruption
    °íÁ¤¾à¹°¹ßÁø
  • photoallergic drug eruption
    ±¤¾Ë·¹¸£±â¾à¹°¹ßÁø
  • generic drug name
    ÀϹݾà¸í
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • V-Tech urinalysis system
    V-Tech ¿äºÐ¼®Ã¼°è
  • Wiener system
    À§³Êü°è
  • Wilkerson point system
    ÀªÄ¿½¼Á¡¼öü°è
  • achromatic system
    ¹«»ö°è.
  • acid-base buffer system
    »ê¿°±â¿ÏÃæ°è
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal system
    ºÎ½Å°è(Üùãìͧ).
  • aerospace life support system
    (Ç×°ø)¿ìÁÖ¿ë »ý¸íÀ¯Áö½Ã½ºÅÛ.
  • affectional system
    Á¤µ¿Ã¼°è
  • alimentary system(tract)
    ¼ÒÈ­±â°è(á¼ûùÐïͧ)
  • anemia expert system
    ºóÇ÷Àü¹®°¡½Ã½ºÅÛ
  • annular phased array system, APAS
    À§»óµ¿±âÀ±»ó¹è¿­½Ã½ºÅÛ
  • archicortical system
    ¿ø½ÃÇÇÁú°è(¡­Í§)
  • array system
    ¹è¿­ ÀåÄ¡ (¹è¿­ ü°è)
  • gamma motoneuron system
    °¨¸¶¿îµ¿°è(¡­ê¡ÔÑͧ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • venous network rete ; rete venosum
    Á¤¸Æ¸Á.
  • venous ostium
    Á¤¸Æ¼Ò°ø.
  • venous oxygen pressure
    Á¤¸Æ»ê¼Ò¾Ð (ð¡Øæß«áÈäâ).
  • venous oxygen reserve
    Á¤¸Æ»ê¼Ò¿¹ºñ (¡­çãÝá).
  • venous part
    Á¤¸ÆºÎºÐ
  • venous phase
    Á¤¸Æ±â
  • venous plexus
    Á¤¸Æ,¾ó±â
  • venous plexus
    Á¤¸Æ¾ó±â, Á¤¸ÆÃÑ(ð¡Øæõ¿).
  • venous plexus
    Á¤¸Æ¾ó±â
  • venous plexus of foramen ovale
    Ÿ¿ø±¸¸ÛÁ¤¸Æ¾ó±â
  • venous plexus of hypoglossal canal
    Çô¹Ø½Å°æ°üÁ¤¸Æ¾ó±â
  • venous pressure
    Á¤¸Æ¾Ð(ð¡Øæäâ)
  • venous pressure
    Á¤¸Æ¾Ð(ð¡Øæäâ).
  • venous pulse
    Á¤¸Æ¸Æ¹Ú(ð¡ØæØæÚÑ).
  • venous return
    Á¤¸ÆÈ¯·ù(ð¡Øæü½×µ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
PNS paraneoplastic syndrome; parasympathetic nervous system; partial nonprogressive stroke; peripheral n...
PPS Personal Preference Scale; physician, patient and society [course]; polyvalent pneumococcal polysacc...
RAS rapid atrial stimulation; recurrent aphthous stomatitis; reflex activating stimulus; reliability, av...
SCS Saethre-Chotzen syndrome; shared computer system; silicon-controlled switch; Society of Clinical Sur...
SIS semantic indexing system; serotinin irritation syndrome; simian sarcoma; simulator-induced syndrome;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
IVDU Intravenous drug use
IDU Intravenous drug users
IND Investigational New Drug
IND Investigational New Drug Application
MDR Multi drug resistance
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • prescription drug
    ó¹æ ¾à
  • protein-drug complex
    ´Ü¹é-¾à¹° º¹ÇÕü
  • storage of drug
    ¾à¹°ÀÇ º¸°ü
  • sulfa drug
    ¼³ÆÄÁ¦
  • sustained action drug
    ÁöÈ¿¼º ¾àÁ¦
  • sustained release drug
    ÁöÈ¿¼º ¾àÁ¦
  • topical dental drug
    µµÆ÷¿ë Ä¡°ú ¾àÁ¦
  • tranquilizing drug
    Á¤¿ÂÁ¦, Á¤½Å ¾ÈÁ¤Á¦
    °¨Á¤ »óÅ¿¡ ÀÛ¿ëÇÏ´Â ¾à¹°·Î¼­, ȯÀÚÀÇ ÀǽÄÀ» ȥʽÃŰÁö ¾Ê°í Á¶¿ëÈ÷ ¶Ç´Â Æò¿ÂÇÏ°Ô ÇÏ´Â °Í. À̰ÍÀº ±Ù½É, °ÆÁ¤ »óÅÂ, ½Å°æÁõ ¹× Á¤½Å Àå¾Ö µîÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù.
  • untoward drug effect
    ¾à¹°ÀÇ ¹Ù¶÷Á÷ÇÏÁö ¾Ê´Â È¿°ú
    ¿ì¸®°¡ ¿øÇÏ´Â Ä¡·á ¸ñÀû¿¡ ºÎÇÕÇÏ´Â ¾à¸® ÀÛ¿ëÀÌ ¾Æ´Ï¶ó ÀÎü¿¡ ÇØ°¡µÇ´Â µ¶ ÀÛ¿ë ¶Ç´Â ºÎÀÛ¿ë.
  • ABO blood group system
    ABO Ç÷¾×Çü°è, ABO Ç÷¾×Çü °èÅë
    A, B´Â ¿ì¼º, O´Â ¿­¼ºÀ¸·Î¼­, A, B, AB, OÇüÀÌ ÀÖ´Ù.
  • ABO system
    ABO Çü, ABO °èÅë
  • achromatic system
    ¹«»ö°è
  • aerospace life support system
    ¿ìÁÖ¿ë »ý¸í À¯Áö ½Ã½ºÅÛ
  • affecting multiple system
    ´Ù¹ß¼º °èÅëÀ» ħ¹üÇÑ
  • affectional system
    Á¤µ¿ ü°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
drug design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
(12 Dec 1998)
drug development pathway The various procedures and studies that must be undertaken to satisfy Food and Drug Administration requirements for drug approval and marketing.
(14 Nov 1997)
drug eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.
(12 Dec 1998)
drug evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
(12 Dec 1998)
drug-fast Pertaining to microorganisms that resist or become tolerant to an antibacterial agent.
(05 Mar 2000)
drug fever Fever resulting from an allergic reaction to a drug that clears rapidly on discontinuation of the drug.
(05 Mar 2000)
drug half-life The amount of time it takes for one-half of an administered drug to be lost through biological processes (metabolism and elimination).
(27 Sep 1997)
drug holiday Interval when a chronically medicated patient temporarily stops taking the medication; used to allow some recuperation of normal functions, to maintain sensitivity to the drug, and to reduce the likelihood of side-effects.
(05 Mar 2000)
drug hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
(12 Dec 1998)
drug implants Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.
(12 Dec 1998)
drug incompatibility <pharmacology> The quality of not being miscible with another given substance without a chemical change.
One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction.
(12 Dec 1998)
drug-induced cholestasis <hepatology> A condition where a drug is interfering with the normal flow of bile from the liver to the gut via the biliary tract. The end result is jaundice.
Origin: Gr. Stasis = stoppage
(27 Sep 1997)
drug-induced diarrhoea <gastroenterology> Diarrhoea may be produced by several mechanisms. Laxatives may produce diarrhoea by increasing the flow of water into the intestine or by increasing the intestinal motility.
Antibiotic medications can cause diarrhoea by killing the normal bacteria that live in the intestine and help us digest our food. Some drugs produce diarrhoea as a side effect or as drug toxicity.
(27 Sep 1997)
drug-induced disease <pharmacology> A toxic reaction to or morbid condition resulting from the administration of a drug.
(05 Mar 2000)
drug-induced eosinophilic lung disease <radiology> Diffuse reticular pattern: nitrofurantoin, Loeffler-like pattern: penicillin, sulfonamides, ASA, para-ASA, imipramine, HCTZ, cromolyn sodium see: eosinophilic lung disease
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á